INS and fatty liver disease: Consistent with our previous studies in rodents and non‐human primates (Abulizi et al., 2017, 2019, 2020; Goedeke et al., 2019; Perry et al., 2013), daily oral delivery of CRMP was able to significantly reduce hepatic steatosis and improve hepatic insulin sensitivity due to alterations in hepatic DAG content and PKCε translocation.